China Regenerative Medicine International Limited (CRMI, Stock Code: 8158) announced the formal termination of a discloseable transaction related to the subscription of increased registered capital in the target company by CRMI Health. This follows earlier announcements on 29 December 2023, 15 January 2024, and 2 February 2024.

According to the company, certain conditions precedent specified in the Capital Increase and Subscription Agreement were not fulfilled or waived by the agreed date. Following changes in the company’s business strategy and management, the parties entered into a termination agreement on 31 October 2025. As a result, all parties agreed that no claims are to be made against one another, other than rights and liabilities accrued prior to termination.

It was further noted that the Capital Increase and Subscription Agreement would have automatically terminated if the conditions precedent were not satisfied or waived before the Long Stop Date. The board stated that this formal termination is procedural and does not materially affect the arrangement previously agreed upon.

The company emphasized that the termination will not have any material adverse impact on its business operations, financial position, or shareholders’ interests.